Mounjaro for weight loss and how tirzepatide works

Safety info: Compounded semaglutide and tirzepatide are not FDA-approved. GLP-1 medicines may cause serious side effects, including possible thyroid tumors. Do not use if you or your family have a history of MTC or MEN 2. Full safety information

Mounjaro is Eli Lilly’s brand name for tirzepatide, a once-weekly injection that activates both GLP-1 and GIP receptors to curb appetite, slow digestion and improve blood sugar control. The FDA approved Mounjaro for type 2 diabetes, and the same drug is sold as Zepbound for chronic weight management. In the SURMOUNT-1 trial, adults without diabetes who took tirzepatide lost more weight on average over 72 weeks than those on placebo. Results vary from person to person, and weight tends to return when the medication stops.

Mounjaro and Zepbound compared

Mounjaro and Zepbound are two brand names for tirzepatide, both made by Eli Lilly and both sold in doses from 2.5 mg to 15 mg. What separates them is the use each one is approved for. The FDA approved Mounjaro in May 2022 as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. It approved Zepbound in November 2023 for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related health condition.

Detail	Mounjaro	Zepbound
Manufacturer	Eli Lilly	Eli Lilly
Active ingredient	Tirzepatide	Tirzepatide
Main FDA-approved use	Blood sugar control in adults with type 2 diabetes, alongside diet and exercise	Chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, alongside a reduced-calorie diet and more physical activity
First approved	May 2022	November 2023
Form and dose range	Once-weekly injection, 2.5 mg to 15 mg	Once-weekly injection, 2.5 mg to 15 mg

The Mounjaro name stuck because it came first. It reached the market about 18 months before Zepbound, and the weight loss people saw and talked about during that time was attached to the only tirzepatide brand available. That is why so many people still search for Mounjaro when they are looking into weight loss treatment.

The label has practical consequences. Insurers generally tie coverage to the approved use, so a Mounjaro prescription for someone without diabetes can meet a different coverage decision than a Zepbound prescription written for weight management. The indication also shapes prior authorization paperwork and what appears in your medical record.

How tirzepatide works in the body

Tirzepatide is a dual receptor agonist. It activates two gut hormone receptors at once: the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Both hormones are incretins, released by the gut after you eat to help the body handle food and blood sugar. As the NIH clinical pharmacology review of tirzepatide explains, semaglutide and similar drugs act on the GLP-1 receptor alone.

GLP-1 receptor activation has three well-described effects:

• Slower stomach emptying. Food moves from the stomach into the small intestine more slowly, so the feeling of fullness after a meal lasts longer.
• Less hunger. It acts on appetite pathways in the brain, which makes it easier to eat less without constant cravings.
• Glucose-dependent insulin release. The pancreas releases more insulin when blood sugar rises after eating, without pushing blood sugar down at rest.

GIP receptor activation appears to strengthen these GLP-1 effects and may also influence how fat tissue stores and uses energy. Researchers are still working out that pathway, and it is easy to overstate what is known. What the trials do show is that the combination produces more weight loss than a GLP-1-only drug, as the head-to-head results below describe. Our explainer on GIP vs GLP-1 and what dual agonist means covers the biology in more depth.

What the SURMOUNT trials studied

SURMOUNT is a series of phase 3 randomized trials that tested tirzepatide for weight management in different groups of people. Their published results describe the brand-name drug under trial conditions and are linked below.

SURMOUNT-1

SURMOUNT-1, published in the New England Journal of Medicine, enrolled adults with obesity or overweight who did not have type 2 diabetes and followed them through 72 weeks of once-weekly tirzepatide at 5, 10 or 15 mg, or placebo. Average weight loss was greater with each tirzepatide dose than with placebo, and greater at the higher doses.

Results were averages across large groups, so some participants lost more and some lost less. Participants also received structured lifestyle counseling during the trial, and that support is part of what the results reflect.

Tirzepatide compared with semaglutide

SURMOUNT-5 was the first direct head-to-head trial of tirzepatide and semaglutide in people with obesity. Over 72 weeks, average weight loss was greater with tirzepatide than with semaglutide, as summarized in a comparative review in Frontiers in Medicine. Real-world comparative research has pointed in the same direction. For a fuller look at how the two drugs differ in dosing, side effects and cost, see our guide to semaglutide vs tirzepatide.

Why real-world results can differ

Trial conditions are hard to reproduce. The dose a person reaches, their starting weight and metabolic history, how consistently doses are taken, and the nutrition and behavioral support around treatment all affect results. Trials in adults with type 2 diabetes have generally shown smaller average weight loss than SURMOUNT-1, so people taking Mounjaro for diabetes may want to set expectations with that in mind. SURMOUNT-4, which looked at what happens after people stop, is covered further down.

Who may be a candidate for tirzepatide

The FDA prescribing information for Zepbound sets two thresholds for adults: a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidemia, obstructive sleep apnea or cardiovascular disease. In both cases the drug is meant to be used alongside a reduced-calorie diet and more physical activity. Meeting the BMI criteria is where an evaluation starts. A prescriber still has to review your history before deciding whether tirzepatide fits.

Who should not take tirzepatide

Tirzepatide carries an FDA boxed warning, the agency’s most serious label warning, for thyroid C-cell tumors seen in rodent studies. It should not be used by people with:

• A personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• A previous serious allergic reaction to tirzepatide or any ingredient in the product, such as anaphylaxis or angioedema

A self-screening quiz cannot settle these questions. They need a clinician who has reviewed your personal history, family history and past drug reactions.

Conditions that need a closer look

Tirzepatide is not recommended for people with severe gastrointestinal disease, including gastroparesis, and it has not been studied in people who have had pancreatitis. Gallbladder disease, significant kidney problems, an active eating disorder, and pregnancy or plans to become pregnant also call for a careful conversation with the prescriber before starting.

Other medications matter as well. People taking insulin or insulin secretagogues such as sulfonylureas have a higher risk of low blood sugar when tirzepatide is added, and the dose of the existing drug often needs to come down. That change should be decided and documented by a prescriber before the first dose. As a clinical review of obesity pharmacotherapy puts it, treating obesity with medication calls for the same review of history, medications and metabolic status as managing any other chronic disease.

Dosing, titration and side effects

How the dose is increased

Tirzepatide starts at 2.5 mg once weekly. The dose then rises in 2.5 mg steps, no sooner than every four weeks, through 5 mg, 7.5 mg, 10 mg and 12.5 mg to a maximum of 15 mg weekly. The slow climb gives the body time to adjust and is the main tool for keeping side effects manageable. At each step, the prescriber decides whether to move up, hold the current dose or step back, based on how well you tolerate it and how you are responding. Our tirzepatide dosage chart explains what each stage is for.

Moving up too quickly tends to make digestive symptoms worse and makes people more likely to stop early. Skipping injections or cutting doses on your own to cope with nausea can lead to the same outcome, so side effects are worth raising with the care team as soon as they appear.

Common side effects

Gastrointestinal effects are the most common: nausea, diarrhea, constipation and vomiting, and less often reflux. They are dose-dependent and cluster in the escalation phase, when the body meets a new dose for the first time, and they tend to ease as it adjusts. A peer-reviewed review of tirzepatide adverse events catalogues the full range reported in research.

Injection-site reactions such as redness or swelling are common and usually short-lived. Some people also feel tired during the first weeks at a new dose. When symptoms persist, a clinician may slow the titration, hold or lower the dose, adjust timing, or check whether something more serious is going on. Our guide to Mounjaro side effects and how to manage them goes into more detail.

Serious risks to know about

• Pancreatitis. Severe abdominal pain needs immediate medical attention.
• Gallbladder disease. Acute gallbladder problems are a documented precaution, and clinicians should watch for them throughout treatment.
• Low blood sugar. The risk rises when tirzepatide is combined with insulin or insulin secretagogues.
• Dehydration and kidney strain. Fluid loss from vomiting or diarrhea is a known pathway to acute kidney injury.
• Thyroid C-cell tumors. This is the subject of the boxed warning described above.

Cleveland Clinic’s guidance on tirzepatide stresses regular contact with your provider throughout treatment, since that contact is how these risks are monitored and caught early.

What supervised treatment involves

Evidence-based guidance on obesity pharmacotherapy places medication within long-term treatment that relies on repeated clinical review. The World Health Organization’s global guideline on GLP-1 medicines for obesity, issued in December 2025, likewise treats structured clinical oversight as part of GLP-1 treatment itself. In practice, supervised tirzepatide care usually includes these pieces:

• A medical intake. A licensed clinician reviews your medical and family history, current medications, contraindications, BMI, relevant metabolic markers and goals before prescribing.
• Baseline labs. A pre-treatment panel gives a reference point for measuring change later.
• Guided titration. The prescriber makes dose changes based on tolerance and response.
• A way to reach the care team. Side effects peak during dose escalation, so being able to report symptoms and get a clinical answer matters most in the first few months.
• Repeat labs. Periodic testing shows how your metabolic health is responding and can flag changes that call for a dose adjustment.
• Nutrition and habit support. Coaching on protein, eating patterns and activity helps build routines that can outlast the prescription.

Labs also help when progress stalls. A plateau can reflect how you are responding to the medication or an underlying factor such as thyroid dysfunction, insulin resistance or hormonal change, and the scale alone cannot tell those apart.

Researchers have described a clinical support gap in telehealth GLP-1 care, where easy access to a prescription is not matched by the ongoing care around it. Before signing up with any program, it is reasonable to ask who reviews your history, how dose changes are decided, whether labs are included, and how you reach a clinician between visits.

What happens when you stop tirzepatide

In SURMOUNT-4, participants who stopped tirzepatide after an initial treatment period regained a substantial share of the weight they had lost within the following year. The American College of Cardiology’s review of SURMOUNT-4 treated that regain as a cardiovascular concern. A post hoc analysis published in JAMA Internal Medicine in November 2025 found that as weight returned, many of the improvements in blood pressure, lipids and blood sugar control reversed with it.

The explanation is biological. On tirzepatide, appetite is lower and fullness comes sooner. When the drug stops, the body’s earlier hunger signals and eating patterns tend to return. That is a predictable response and has little to do with willpower, and it is one reason clinicians increasingly treat obesity as a chronic condition that needs ongoing management.

Two practical points follow. First, the months on medication are the best time to build habits that help hold results, such as regular protein at meals, consistent physical activity and a better read on hunger and fullness. Second, any decision to lower the dose or stop should be planned with your prescriber. Our guide on how to taper off a GLP-1 without regaining weight covers what that plan can look like.

Cost, coverage and access

Brand-name tirzepatide is expensive without insurance, and cash prices change often, so check current pricing directly. Coverage follows the approved use: Mounjaro is usually covered under a diabetes benefit, while Zepbound falls under obesity coverage, which varies by insurer and employer. Prior authorization is common and may require a documented BMI and a record of earlier lifestyle efforts. Manufacturer savings cards can lower costs for people with commercial insurance, and Medicare and Medicaid rules for weight-management drugs differ from commercial plans and have been changing.

When comparing telehealth programs, look past the headline monthly price. Some advertised prices cover only the medication, with lab work, follow-up visits and dose-change appointments billed separately. Ask what is included before you commit. Our breakdown of tirzepatide cost without insurance walks through the main options.

Compounded tirzepatide

Compounded tirzepatide is prepared by a state-licensed compounding pharmacy for an individual patient, usually as an injection, under a prescription that documents that patient’s clinical need. It is not FDA-approved, and FDA does not review compounded medications for safety, effectiveness or quality. It is not a generic of Mounjaro or Zepbound, and it was not the product studied in the SURMOUNT trials, so the trial results above describe the brand-name drug only.

Compounding rules narrowed after FDA declared the national tirzepatide shortage over in late 2024, and the agency has since clarified its policies for compounders and set out its concerns about unapproved GLP-1 drugs used for weight loss. Our guide to compounded tirzepatide and what is legal covers the regulatory detail. If you are considering a compounded option, check:

• That the pharmacy holds current state licensure and follows sterile compounding practices
• Whether batches are tested by an accredited third-party lab, and whether a certificate of analysis confirming potency and sterility is available
• Whether the pharmacy sources its active ingredient from FDA-registered suppliers
• That a licensed prescriber reviews your history, medications and contraindications before prescribing and stays involved as the dose changes

Frequently asked questions

Can I take Mounjaro for weight loss if I don’t have diabetes?

Mounjaro’s FDA approval is for type 2 diabetes. Before Zepbound existed, clinicians commonly prescribed Mounjaro off-label for weight loss, which is a legal practice. Today Zepbound is the tirzepatide brand approved for chronic weight management, and because insurers generally cover drugs for their approved use, a Mounjaro prescription without a diabetes diagnosis may run into coverage problems.

How long does it take to see results on tirzepatide?

Weight loss is gradual. Treatment starts at a low dose meant for tolerability and rises over several months, and the SURMOUNT-1 results were measured after 72 weeks. Your clinician will look at the trend over months, along with labs and how you feel, more than at week-to-week changes.

Can tirzepatide cause low blood sugar?

Tirzepatide’s effect on insulin is glucose-dependent, meaning it mainly increases insulin release when blood sugar rises after eating. The risk of low blood sugar goes up when it is combined with insulin or insulin secretagogues such as sulfonylureas, and the doses of those drugs often need to be lowered. Tell your prescriber about every glucose-lowering medication you take.

Is tirzepatide available as a pill?

No. Mounjaro and Zepbound are once-weekly injections, and there is no oral form of tirzepatide. At Elara, compounded tirzepatide is given as a weekly injection, and the only tablet option is compounded semaglutide, taken daily.

What lab tests are done before and during tirzepatide treatment?

A typical baseline panel includes HbA1c, fasting glucose, a lipid panel, liver enzymes and kidney function. Repeating these tests over time shows how your metabolic health is responding beyond what the scale shows, and it can flag early changes that call for a dose adjustment. Your prescriber decides which tests you need and how often.

Tirzepatide treatment at Elara

Elara Health and Wellness offers compounded tirzepatide by weekly injection as part of a telehealth weight-care program. Care comes from licensed clinicians with OpenLoop Healthcare Partners, PC, a board-certified physician-led team of physicians, nurse practitioners and physician assistants. A clinician reviews your health information to decide whether treatment is appropriate, and there is no charge if you are not approved. Compounded medications are prepared by state-licensed pharmacies for individual patients and are not FDA-approved, and FDA does not review them for safety, effectiveness or quality. Elara also offers compounded semaglutide by weekly injection or daily tablet.

The program includes:

• Quarterly metabolic labs at Quest or Labcorp
• A certified health coach every 3 weeks, with the first call around week 3
• Secure messaging with the care team, answered during business hours
• Approved medication that typically ships within a week, with shipping included
• The same price at every dose, with longer terms prepaid upfront

Availability depends on your state and clinical eligibility. You can read more about Elara’s tirzepatide weight loss program, or take the free assessment to find out whether treatment may be a fit for you.

Compounded medications are prepared by state-licensed pharmacies for individual patients and are not FDA-approved. This article is for general information and is not medical advice. Talk with a licensed clinician about whether GLP-1 treatment is right for you.

Ozempic®, Wegovy® and Rybelsus® are registered trademarks of Novo Nordisk A/S, and Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Neither company is affiliated with Elara Health and Wellness.